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Background: The purpose of this study was to assess the effect of bevacizumab in maintaining 
intraocular pressure lowered by trabeculectomy in refractory open-angle glaucoma.
Methods: Thirty-seven eyes from 37 patients referring to Nikoukari Ophthalmology   University 
Hospital in Tabriz were enrolled in this randomized clinical trial. Seventeen patients were 
  randomly assigned to receive bevacizumab augmentation after trabeculectomy, and 20 patients 
were assigned to a control group receiving a placebo injection of normal saline. Bevacizumab 
was injected subconjunctivally at a dose of 0.2 mg. Intraocular pressure was measured on eight 
occasions, ie, at baseline, 24 hours, 3 days, 7 days, 2 weeks, 1 month, 2 months, and 3 months 
after treatment.
Results: Men constituted 81% of the participants, who were of mean age 67.5 years.   Twenty-nine 
patients had secondary open-angle glaucoma, while eight patients had primary open-angle 
glaucoma. Intraocular pressure decreased from a mean of 28.4 mmHg at baseline to a mean 
of 12.1 mmHg during the first day and to 15.1 mmHg after 3 months. Adding bevacizumab to 
trabeculectomy was not found to affect intraocular pressure differently to placebo. Neither the 
results of repeated measurements analysis nor single comparison statistical tests were significant 
for a difference in efficacy of bevacizumab versus placebo.
Conclusion: Subconjunctival bevacizumab 0.2 mg was not found to affect the trend in 
  intraocular pressure more than placebo after trabeculectomy for open-angle glaucoma.
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Introduction
Fibroblast proliferation and subsequent scar formation at the surgical site is the main 
reason for failure of filtering surgery. Antimetabolites, such as mitomycin C and 
5-fluorouracil, have been used to modify the wound healing response and to prevent 
bleb failure. Research has showed these two methods to be effective in augmenting 
trabeculectomy.1–6 However, they have not proven to be fully satisfactory, and research 
is ongoing to identify and test other alternatives. Considering the essential role of angio-
genesis in the proliferative phase of wound healing and the pathological process in bleb 
failure after trabeculectomy, researchers have thought of using antiangiogenesis agents 
to slow this process after filtration surgery. Bevacizumab (Avastin®) is an antivascular 
endothelial growth factor agent of interest in this regard, both for neovascular and 
other types of glaucoma research. However, evidence for its efficacy in augmentation 
of filtration surgery is very limited. Only a few quite small-sized studies are avail-
able, most of them being case series. The aim of this study was to assess the effect of Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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bevacizumab in maintaining intraocular pressure lowered by 
trabeculectomy in refractory open-angle glaucoma.
Methods
A randomized clinical trial was conducted at the   Nikoukari 
Ophthalmology University Hospital in Tabriz, Iran. 
  Thirty-seven eyes from 37 patients were included. Nearly half 
of the patients had bilateral glaucoma. For these patients, the 
eye being more refractory to treatment, they were enrolled 
into the study. Using simple randomization for a parallel 
trial design, 17 patients were randomly assigned to receive 
bevacizumab (Roche, Basel, Switzerland) augmentation after 
trabeculectomy, and 20 patients were assigned to a control 
group receiving a normal saline injection as a placebo after 
trabeculectomy. After fornix-based trabeculectomy 8–10 mm 
from the bleb, bevacizumab was injected subconjunctivally 
at a dose of 0.2 mg in the active treatment group, and normal 
saline was injected in a similar manner into the subconjunc-
tiva in the placebo-treated group.
A simple randomization method was used to allocate the 
patients to receive either bevacizumab or placebo injection 
after trabeculectomy. Unlike block randomization, simple 
randomization does not ensure an equal number of patients 
in both arms of the study, but it does ensure a probabilistic 
status. The study was double-blinded such that neither patient 
nor the surgeon knew the type of treatment administered. To 
ensure blinding, an ophthalmology resident was responsible 
for preparation of the injection syringes, such that their con-
tent was not identifiable to the surgeon.
The inclusion criteria for this study were primary 
or secondary open-angle glaucoma and uncontrolled 
intraocular pressure. The exclusion criteria were age under 
40 years, increased intraocular pressure due to neovascular 
inflammation, aphakic glaucoma, and traumatic glaucoma. 
Patients were followed up for measurement of intraocular 
pressure and any development of complications. Intraocu-
lar pressure was measured in eight occasions, ie, at base-
line, 24 hours, 3 days, 7 days, 2 weeks, 1 month, 2 months, 
and 3 months after treatment. The primary endpoint of the 
study was the intraocular pressure measurement trend on 
a continuous scale.
Statistical analysis
Data were analyzed using STATA statistical software pack-
age (v 11; College Station, TX). Trends in intraocular pres-
sure were compared between groups at evaluation sessions 
throughout the study. Mean and median tests were also 
used to compare intraocular pressure between the groups. 
Considering the placebo-controlled design of the trial, the 
statistical tests were done in a one-sided manner, giving 
higher power to the study. Test results with a P-value lower 
than 0.05 were considered to be statistically significant. The 
study protocol was approved by the committee of ethics at 
Tabriz University of Medical Sciences.
Results
Men constituted 81% of the participants. The mean patient 
age was 67.5 (range 48–83) years, with a standard deviation 
(SD) of 10 years. Twenty-nine patients had secondary open-
angle glaucoma, and eight patients had primary open-angle 
glaucoma. Nineteen right and 18 left eyes were operated on, 
and the distribution was not different between the groups. 
The mean cup-to-disc ratio was 0.9 ± 0.16, and this was not 
statistically different between the two treatment groups. 
Mean corneal thickness was 517.6, and this was not statisti-
cally different between the groups.
Overall, mean intraocular pressure deceased significantly 
just shortly after surgery, from a mean of 28.4 mmHg at 
baseline to a mean of 12.1 mmHg on the first day and to 
15.1 mmHg after 3 months. This decrement was statistically 
significant (P , 0.001) at both time points. As shown in 
  Figure 1, the intraocular pressure decreased sharply on the first 
day and reached a plateau during the first 2 weeks, thereafter 
increasing to another plateau 1 month after treatment, then 
staying rather stable for the rest of the follow-up period.
Descriptive statistics for intraocular pressure were com-
pared between the treatment groups, as shown in Table 1. 
Adding bevacizumab to trabeculectomy was not found to 
affect intraocular pressure more than placebo. Neither results 
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Figure 1 error bar graph of intraocular pressure evaluated at baseline and several times 
after surgery for all patients. Middle circle represents the mean intraocular pressure, 
and the bars show the 95% confidence intervals of mean intraocular pressure.
Abbreviation: iOP, intraocular pressure.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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of repeated measurement analysis nor single comparison 
statistical tests were significant for a difference in efficacy of 
bevacizumab compared with placebo when used after trab-
eculectomy for glaucoma. Table 1 shows that the transiently 
lower intraocular pressure effect of bevacizumab disappears 
1 month after treatment. No serious complication from beva-
cizumab was recorded in this study.
Discussion
Well vascularized blebs have been shown to be associated 
with a poorer prognosis than less vascular blebs.7 The effects 
of angiogenesis inhibitors on Tenon’s fibroblast prolifera-
tion and migration define the antifibroblastic properties of 
the antivascular endothelial growth factor agents, including 
bevacizumab. Although the antiangiogenic effects of these 
agents make them applicable for neovascular glaucoma, the 
discovery that antivascular endothelial growth factor has anti-
fibroblastic effects has led researchers to think of using these 
agents to augment glaucoma filtration surgery, in the hope 
of delaying or reducing the bleb failure rate.8 Bevacizumab 
is an antivascular endothelial growth factor agent thought 
to be potentially applicable in increasing bleb survival after 
trabeculectomy for glaucoma. Few studies have addressed 
this issue, and have used different methodologies.
Studies of the in vitro effects of bevacizumab on human 
corneal and conjunctival fibroblast cell lines have been 
controversial.9,10 A recent animal study showed that subcon-
junctival bevacizumab after trabeculectomy improved bleb 
survival.11 Human studies are quite limited in this regard. Choi 
et al reported the results of their case series comprising six 
refractory glaucomatous eyes. They administered subconjunc-
tival bevacizumab 1.25 mg after trabeculectomy augmented 
with mitomycin C. Based on the favorable results of this study, 
they have suggested that subconjunctival bevacizumab may 
be effective in improving the efficacy of trabeculectomy.12 
However, definitive conclusions   regarding the efficacy of a 
treatment are not usually expected to be drawn from a case 
series, and the situation is much more complex in their study 
because of the concomitant use of mitomycin C. A few fur-
ther case reports and case series have also discussed the role 
of bevacizumab in trabeculectomy, but suffer similar study 
limitations.13–17
In a pilot study, Grewal et al used bevacizumab 1.25 mg by 
subconjunctival injection after trabeculectomy in 12 patients. 
Mean intraocular pressure in their study decreased from 
24.4 mmHg to 8.3 mmHg during the first day, and increased 
slightly in the following 3 months.18 Their study lacked a 
control group, making it near impossible to separate the 
effect of bevacizumab from the effect of surgery. We did 
not observe any significant difference between our placebo 
and bevacizumab groups, and any trivial nonsignificant dif-
ferences disappeared over time. In our study, we found two 
intraocular pressure plateaus suggestive of decayed efficacy 
of treatment, so repeated injections may be necessary, even 
if bevacizumab is found to be effective.19,20
In interpreting the findings of our study, it should be taken 
into account that, although it was not a large-scale study and 
lower statistical power may explain its results, it is the largest 
study to date when compared with other published research 
using a similar study design. Another point needing attention 
is the lower dose of drug and also the fact that, in contrast 
with most previous studies, neovascular glaucoma was an 
exclusion criterion in our study.
Conclusion
Single-dose subconjunctival bevacizumab 0.2 mg was not 
found to affect the intraocular pressure trend in a way that 
was significantly different from placebo when administered 
to augment filtration surgery in refractory glaucomatous eyes, 
and any trivial drug effect decayed over time. Of note is that 
this study was conducted with a 3-month evaluation period 
and, although this length of time was sufficient to detect 
decay of efficacy, future studies with larger sample sizes and 
longer periods of evaluation are warranted.
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